Presently, vesicular monoamine transporter 2 (VMAT-2) inhibitors are the only option used to overcome the release of dopamine from the presynaptic junction and are used for the symptomatic relief of TD [10]. This evidence concerns the gene SLC18A2 and thanatophoric dysplasia.